Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 118, Issue 4-5, 2010, Pages 219-230

  Song, Robert X D ^a   Chen, Yuchai ^a   Zhang, Zhenguo ^a   Bao, Yongde ^a   Yue, Wei ^a   Wang, Ji Ping ^a   Fan, Ping ^a   Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aromatase; Breast cancer; EGF R; Estradiol; Estrogen; Estrogen receptor; IGF 1 R; MAP kinase; Non genomic; PI 3 kinase

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRADIOL;

BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL GROWTH; CELL MEMBRANE; CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; EXPRESSION VECTOR; HORMONE RESISTANCE; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; APOPTOSIS; ARTICLE; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 77950346929     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.09.018     Document Type: Conference Paper

References (32)

1. S. Ali, R.C. Coombes, Estrogen receptor alpha in human breast cancer: occurrence and significance, J. Mammary Gland Biol. Neoplasia 5 (2000) 271-281.
2. D. Yee, A.V. Lee, Crosstalk between the insulin-like growth factors and estrogens in breast cancer, J. Mammary Gland Biol. Neoplasia 5 (2000) 107-115.
3. B.J. Cheskis, Regulation of cell signalling cascades by steroid hormones, J. Cell Biochem. 93 (2004) 20-27.
4. V.I. Alexaki, I. Charalampopoulos, M. Kampa, et al., Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation, FASEB J. 18 (2004) 1594-1596.
5. R. Baserga, C. Sell, P. Porcu, M. Rubini, The role of the IGF-I receptor in the growth and transformation of mammalian cells, Cell Prolif. 27 (1994) 63-71.
6. H.S. Earp III, B.F. Calvo, C.I. Sartor, The EGF receptor family-multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4, Trans. Am. Clin. Climatol. Assoc. 114 (2003) 315-333.
7. R.X. Song, C.J. Barnes, Z. Zhang, Y. Bao, R. Kumar, R.J. Santen, The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasmamembrane, Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2076-2081.
8. S. Kahlert, S. Nuedling, M. van Eickels, H. Vetter, R. Meyer, C. Grohe, Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway, J. Biol. Chem. 275 (2000) 18447-18453.
9. R.J. Pietras, Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature, Breast J. 9 (2003) 361-373.
10. J.M. Gee, J.F. Robertson, E. Gutteridge, et al., Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer, Endocr. Relat. Cancer 12 (Suppl. 1) (2005) S99-S111.
11. R. Nahta, L.X. Yuan, B. Zhang, R. Kobayashi, F.J. Esteva, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells, Cancer Res. 65 (2005) 11118-11128.
12. F.L. Roudabush, K.L. Pierce, S. Maudsley, K.D. Khan, L.M. Luttrell, Transactivation of theEGFreceptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells, J. Biol. Chem. 275 (2000) 22583-22589.
13. T. Ahmad, G. Farnie, N.J. Bundred, N.G. Anderson, The mitogenic action of insulin-like growth factor I in normalhumanmammaryepithelial cells requires the epidermal growth factor receptor tyrosine kinase, J. Biol. Chem. 279 (2004) 1713-1719.
14. P.O. Hackel, E. Zwick, N. Prenzel, A. Ullrich, Epidermal growth factor receptors: critical mediators of multiple receptor pathways, Curr. Opin. Cell Biol. 11 (1999) 184-189.
15. L.M. Luttrell, Y. Daaka, R.J. Lefkowitz, Regulation of tyrosine kinase cascades by G-protein-coupled receptors, Curr. Opin. Cell Biol. 11 (1999) 177-183.
16. E. Zwick, P.O. Hackel, N. Prenzel, A. Ullrich, The EGF receptor as central transducer of heterologous signalling systems, Trends Pharmacol. Sci. 20 (1999) 408-412.
17. R.X. Song, G. Mor, F. Naftolin, et al., Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17{beta}-estradiol, J. Natl. Cancer Inst. 93 (2001) 1714-1723.
18. R.X. Song, Z. Zhang, Y. Chen, Y. Bao, R.J. Santen, Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells, Endocrinology 148 (8) (2007) 4091-4101.
19. P. Fan, J. Wang, R.J. Santen, W. Yue, Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells, Cancer Res. 67 (2007) 1352-1360.
20. K. Sato, T. Iwasaki, Y. Fukami, Association of c-Src with p52Shc in mitotic NIH3T3 cells as revealed by Src-Shc binding site-specific antibodies, J. Biochem. (Tokyo) 137 (2005) 61-67.
21. R.X. Song, R.A. McPherson, L. Adam, et al., Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation, Mol. Endocrinol. 16 (2002) 116-127.
22. P. Collins, C. Webb, Estrogen hits the surface, Nat. Med. 5 (1999) 1130-1131.
23. R.B. Dickson, G.M. Stancel, Estrogen receptor-mediated processes in normal and cancer cells, J. Natl. Cancer Inst. Monogr. (2000) 135-145.
24. E.R. Levin, Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor, Mol. Endocrinol. 17 (2003) 309-317.
25. W. Yue, J. Wang, Y. Li, P. Fan, R.J. Santen, Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells, Int. J. Cancer 117 (2005) 746-754.
26. A. Howell, D.J. DeFriend, J.F. Robertson, R.W. Blamey, L. Anderson, E. Anderson, F.A. Sutcliffe, P. Walton, Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer, Br. J. Cancer 74 (1996) 300-308.
27. J.F. Robertson, W. Odling-Smee, C. Holcombe, S.R. Kohlhardt, M.P. Harrison, Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer, Clin. Ther. 25 (2003) 1440-1452.
28. J.F. Robertson, M. Harrison, Fulvestrant: pharmacokinetics and pharmacology, Br. J. Cancer 90 (Suppl. 1) (2004) S7-S10.
29. S. Dauvois, R. White, M.G. Parker, The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling, J. Cell Sci. 106 (Pt 4) (1993) 1377-1388.
30. T. Improta-Brears, A.R. Whorton, F. Codazzi, J.D. York, T. Meyer, D.P. McDonnell, Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium, Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4686-4691.
31. R.I. Nicholson, S.R. Johnston, Endocrine therapy-current benefits and limitations, Breast Cancer Res. Treat. 93 (Suppl. 1) (2005) S3-S10.
32. R. Schiff, S.A. Massarweh, J. Shou, et al., Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators, Cancer Chemother. Pharmacol. 56 (Suppl. 1) (2005) 10-20.